Literature DB >> 1292719

Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile.

R L Sepulveda1, C Parcha, R U Sorensen.   

Abstract

We performed a case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in 15- to 35-year-old Chilean patients born during a period when BCG coverage was incomplete. Our aims were to determine BCG efficacy against pulmonary tuberculosis in young adults, to determine if repeated BCG immunization increased its protective effect, and to determine factors that could explain the failure of BCG immunization in patients with tuberculosis. We studied 68 patients who had pulmonary tuberculosis based on positive AFB in at least 1 of 2 sputum smears, a positive confirmatory culture and compatible chest roentgenogram abnormalities. The control group were 188 individuals without pulmonary tuberculosis seeking medical care for other ailments. The percentage of non-immunized individuals was 13.2 among patients with tuberculosis and 12.2 among controls. The vaccine efficacy calculated from these data was 10%. There was no difference in the percentage of individuals with 1, 2 and 3 BCG scars between tuberculosis patients and controls. The number and percent of individuals exposed to tuberculosis among BCG-immunized and non-immunized tuberculosis patients and controls were similar. No significant differences between BCG-immunized and non-immunized individuals were detected in tuberculosis patients or in the control group. However, tuberculosis patients as a group had significantly lower weight, education level, employment rate and family income than controls. These observations suggest that the development of pulmonary tuberculosis in BCG-immunized young adults is favored by the presence of genetic and/or acquired predisposing factors capable of overriding protective immunity induced by BCG vaccination.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1292719     DOI: 10.1016/0962-8479(92)90043-J

Source DB:  PubMed          Journal:  Tuber Lung Dis        ISSN: 0962-8479


  9 in total

1.  Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein.

Authors:  Marcus A Horwitz; Günter Harth; Barbara Jane Dillon; Sasa Maslesa-Galic
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

2.  Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin.

Authors:  H Martin Vordermeier; Shelley G Rhodes; Gillian Dean; Nilu Goonetilleke; Kris Huygen; Adrian V S Hill; R Glyn Hewinson; Sarah C Gilbert
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

3.  Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination.

Authors:  B M Buddle; D N Wedlock; N A Parlane; L A L Corner; G W De Lisle; M A Skinner
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

4.  CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial.

Authors:  Tereza Masonou; David A Hokey; Timothy Lahey; Alice Halliday; Luis C Berrocal-Almanza; Wendy F Wieland-Alter; Robert D Arbeit; Ajit Lalvani; C Fordham von Reyn
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

5.  Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis.

Authors:  Phetole Walter Mahasha; Duduzile Edith Ndwandwe; Edison Johannes Mavundza; Muki Shey; Charles Shey Wiysonge
Journal:  BMJ Open       Date:  2019-10-15       Impact factor: 2.692

6.  Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.

Authors:  Helen A Fletcher; Rachel Tanner; Robert S Wallis; Joel Meyer; Zita-Rose Manjaly; Stephanie Harris; Iman Satti; Richard F Silver; Dan Hoft; Beate Kampmann; K Barry Walker; Hazel M Dockrell; Uli Fruth; Lew Barker; Michael J Brennan; Helen McShane
Journal:  Clin Vaccine Immunol       Date:  2013-08-28

7.  Tuberculin skin test distribution following a change in BCG vaccination policy.

Authors:  Sei Won Lee; Soo Yeon Oh; Jin Beom Lee; Chang Min Choi; Hee Jin Kim
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

8.  TLR Agonist Augments Prophylactic Potential of Acid Inducible Antigen Rv3203 against Mycobacterium tuberculosis H37Rv in Experimental Animals.

Authors:  Owais Mohammad; Jagdeep Kaur; Gurpreet Singh; Syed Mohd Faisal; Asim Azhar; Mohd Ahmar Rauf; Umesh Dutt Gupta; Pushpa Gupta; Rahul Pal; Swaleha Zubair
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

9.  Direct Growth Inhibitory Effect of Platelet Activating Factor C-16 and Its Structural Analogs on Mycobacteria.

Authors:  Muhammad S Riaz; Anuvinder Kaur; Suha N Shwayat; Shahriar Behboudi; Uday Kishore; Ansar A Pathan
Journal:  Front Microbiol       Date:  2018-09-11       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.